Immunolymphoscintigraphy in breast cancer: Evaluation using 131I- labeled monoclonal antibody B72.3

  • Lorraine M. Fig
  • , Raya S. Brown
  • , Lisa Von Moll
  • , Henry D. Appelman
  • , Ralph Stevens
  • , Jay Harness
  • , David August
  • , Vernon K. Sondak
  • , Alfred E. Chang
  • , Kenneth R. Zasadny
  • , Susan J. Fisher
  • , Jon W. Johnson
  • , Max S. Wicha
  • , David Colcher
  • , Allen S. Lichter
  • , Richard L. Wahl

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Noninvasive axillary lymph node staging was investigated using [131I]murine monoclonal antibody B72.3 in 16 patients with breast cancer scheduled for axillary dissection. [131I]B72.3 was injected into ipsilateral finger webs or around the breast biopsy. Scintigraphy to 72 h and γ-counting/immunohistochemistry of nodes were performed. Specific antibody uptake (%ID/g) and the ratio of specific:nonspecific antibody uptake were not significantly different in tumor-positive versus tumor-negative nodes, suggesting that [131I]B72.3 is unsuitable to discriminate axillary node tumor involvement.

Original languageEnglish
Pages (from-to)251-260
Number of pages10
JournalNuclear Medicine and Biology
Volume25
Issue number3
DOIs
StatePublished - Apr 1998

Keywords

  • Breast neoplasm
  • Iodine radioisotopes
  • Lymphatic metastasis
  • Monoclonal antibodies
  • Radionuclide imaging

Fingerprint

Dive into the research topics of 'Immunolymphoscintigraphy in breast cancer: Evaluation using 131I- labeled monoclonal antibody B72.3'. Together they form a unique fingerprint.

Cite this